Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
tags : Positive save search
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $14.09 0.36% -1.7% |
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
takhzyro children trial positive results
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
Published: 2022-06-30 (Crawled : 23:00) - globenewswire.com
CLDX | $22.69 -15.84% -3.19% |
|
Health Technology
|
| O: -12.61%
H: 2.61%
C: -3.65%
urticaria therapeutics positive study
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
Published: 2022-06-30 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | $3.3 -2.37% -8.28% |
|
|
| O: 31.35%
H: 12.31%
C: -15.08%
alzheimer's therapeutics positive results tdp-43 biomarkers
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
Published: 2022-06-30 (Crawled : 12:20) - biospace.com/
NMTR | $0.2254 -13.57% -4.14% |
|
Health Technology
|
| O: -14.4%
H: 7.09%
C: -15.63%
biopharma positive results
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
TOMDF | $0.0134 |
|
Manufacturing
|
| O: 0.0%
H: 0.75%
C: 0.75%
covid-19 trial tollovir positive biomarkers
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
Published: 2022-06-29 (Crawled : 23:00) - biospace.com/
LXRX | $1.94 4.3% 0.0% |
|
Health Technology
|
| O: -0.93%
H: 15.49%
C: 5.16%
lx9211 positive results diabetic
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
VTYX | $12.69 3.76% 0.0% |
|
Manufacturing
|
| O: -1.15%
H: 0.0%
C: -1.08%
vtx2735 for topline positive
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
TRVI A | $2.905 3.38% -0.36% |
|
Health Technology
|
| O: 21.67%
H: 12.55%
C: -0.81%
treatment trial therapeutics positive results haduvio
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
Published: 2022-06-29 (Crawled : 12:00) - biospace.com/
CANF | $0.8898 -3.28% -1.1% |
|
Health Technology
|
| O: 20.37%
H: 5.66%
C: -3.77%
psoriasis positive results piclidenoson
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
ICVX | $6.41 11.87% 5.06% |
|
|
| O: 1.68%
H: 0.0%
C: 0.0%
ivx-121 candidate for topline vaccine positive results phase 1
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
ETNB 3 d | $3.25 0.93% 0.93% |
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
topline trial positive results
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Published: 2022-06-28 (Crawled : 13:00) - ir.cyclerion.com
CYCN | $0.5975 8.87% 0.0% |
|
Health Technology
|
| O: 8.39%
H: 0.32%
C: -7.82%
cy6463 disease therapeutics positive
WESTERN COPPER AND GOLD ANNOUNCES POSITIVE FEASIBILITY ON CASINO
Published: 2022-06-28 (Crawled : 11:00) - prnewswire.com
WRN | $1.42 5.97% 0.0% |
|
Non-Energy Minerals
|
| O: 4.52%
H: 0.0%
C: -8.64%
positive
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
Published: 2022-06-27 (Crawled : 23:00) - biospace.com/
KZR M | $9.28 12.21% 3.02% |
|
Health Technology
|
| O: -1.99%
H: 2.96%
C: -2.36%
treatment sciences for topline lupus life trial positive results
Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date June 15, 2022
Published: 2022-06-27 (Crawled : 21:00) - globenewswire.com
NDAQ S | $155.63 2.03% 0.93% |
|
Finance
|
| O: 0.17%
H: 0.0%
C: 0.0%
nasdaq positive
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Published: 2022-06-27 (Crawled : 13:20) - biospace.com/
ARTL A | $0.3111 -1.8% -7.26% |
|
Health Technology
|
| O: 1.07%
H: 9.17%
C: -1.64%
art26 pre-clinical positive results
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
NRSN | $3.3 -2.37% -8.28% |
|
|
| O: 54.76%
H: 26.92%
C: -3.85%
als therapeutics positive results biomarkers
Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
AIMD 4 | $0.2895 |
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: 0.0%
covid-19 preclinical positive results
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
BBIO | $9.89 8.92% 2.86% |
|
Health Technology
|
| O: 0.22%
H: 2.22%
C: 1.3%
bbp-711 pharma for kidney trial positive phase 1 potential
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
MRK | $92.42 1.37% -0.45% |
|
Health Technology
|
| O: -0.16%
H: 2.7%
C: 1.3%
FNCTF | News | $11.99 |
|
Communications
|
| O: 0.62%
H: 0.0%
C: -0.35%
lynparza treatment for chmp positive cancer
USA Holiday (Independence Day) in 2 days
Your saved searches
Save your searches and get alerts when important news are released.
Mentioned Today
APPN | News 4 | $47.15 -0.44% 4.22% |
|
Technology Services
ARQQ | News | $6.2 -1.74% -2.54% |
|
Information
CDNA | News | $22.38 4.19% 0.0% |
|
Health Technology
FNCTF | News | $11.99 |
|
Communications
HLF | News | $21.56 5.43% 0.0% |
|
Distribution Services
HYB | News | $9.16 0% |
|
Miscellaneous
NVAX | News 4 | $57.11 11.04% 0.91% |
|
Health Technology
OKTA | News 4 | $95.96 6.15% -0.61% |
|
Technology Services
OSCR | News | $4.57 7.53% 0.0% |
|
PEGA | News | $49.44 3.34% 0.0% |
|
Technology Services
PM | News 4 | $99.72 0.99% -0.07% |
|
Consumer Non-Durables
TDOC | News | $34.83 4.88% -0.4% |
|
Health Services
TILE | News | $12.695 1.24% 0.0% |
|
Producer Manufacturing
UL | News | $46.29 1.0% -0.02% |
|
Consumer Non-Durables
UNLYF | News | $45.67 |
|
Consumer Non-Durables